Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

The real assets portfolio was the primary detractor due to negative returns for energy stocks and U.S. real estate investment ...

Afya's Q2 2025 results were solid, but the stock faces headwinds from market saturation and regulatory changes in Brazil's ...

Tonix's Tonmya received FDA approval, marking the first new fibromyalgia therapy in 15 years and driving a post-market stock ...

IHF offers exposure to large-cap healthcare, AI-driven growth, and demographic trends, with a recent dip creating a strong ...

I've made costly mistakes in my REIT investing journey, lessons that reshaped my approach and strategy. Learn why smarter ...

Healthcare Opportunities Fund offers a compelling way to play the healthcare sector. Read here for an analysis of THQ CEF.

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Read here for insights on economic indicators and growth prospects. See a detailed look at the indicators and what they may ...

I focus only on proven leaders with wide moats, strong innovation, and valuations. See here for an analysis of three 3 ...

Powell Industries (POWL) offers 50% upside potential. Learn about growth in Electric Utility, strategic acquisitions, and ...

Value Line's digital growth offsets print decline, ensuring steady dividends amid modest revenue. Read here for an analysis ...